Skip to main content
SpringerLink
Log in

Fortschritte in der Osteoporosetherapie

Vielfältige Behandlungsmöglichkeiten verbessern auch die Compliance

  • Diplomfortbildung
  • Published:
rheuma plus Aims and scope

Bei der Behandlung der Osteoporose können wir mittlerweile auf eine breite Palette zugelassener Substanzen mit evidenzbasierter Anti-Fraktur-Wirksamkeit zurückgreifen und dadurch den Therapiekomfort unserer Patienten besser berücksichtigen. Gerade die Anzahl neuer Bisphosphonat-Derivate hat zuletzt durch eine einmal jährliche Applikation Ihren Gipfelpunkt erreicht und die Compliance der Patienten sichtlich verbessert.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004 Jan 29;350(5):459–68.

  2. Meunier PJ, Roux C, Ortolani S, Diaz-Curiel M, Compston J, Marquis P, Cormier C, Isaia G, Badurski J, Wark JD, Collette J, Reginster JY. (2009) Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int. ;20(10):1663–73.

    Google Scholar 

  3. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005 May;90(5):2816–22.

  4. Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C, Balogh A, Delmas PD, Meunier PJ. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a fi ve-year, randomized, placebo-controlled trial. Arthritis Rheum. 2008 Jun;58(6):1687–95.

  5. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001 May 10;344(19):1434–41.

  6. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB. Treatment of Osteoporosis with Parathyroid Hormone Study Group. Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med. 2007 Mar 6;146(5):326–39.

  7. Pleiner-Duxneuner J, Zwettler E, Paschalis E, Roschger P, Nell-Duxneuner V, Klaushofer K. Treatment of osteoporosis with parathyroid hormone and teriparatide. Calcif Tissue Int. 2009 Mar;84(3):159–70.

  8. Ensrud KE, Stock JL, Barrett-Connor E, Grady D, Mosca L, Khaw KT, Zhao Q, Agnusdei D, Cauley JA. Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. J Bone Miner Res. 2008 Jan;23(1):112–20.

  9. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glür CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999 Aug 18;282(7):637– 45. Erratum in: JAMA 1999 Dec 8;282(22):2124.

  10. Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR. Effi cacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol. 2008 Mar;35(3):488–97.

  11. Chesnut III CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004 Aug;19(8):1241–9.

  12. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario- Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007 May 3;356(18):1809–22.

  13. Cranney A, Wells G, Willan A, Griffi th L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002 Aug;23(4):508–16.

  14. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez- Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA. Alendronate Phase III Osteoporosis Treatment Study Group. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004 Mar 18;350(12):1189–99.

  15. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas R, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, for the FREEDOM Trial. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. N Engl J Med 2009; 361:756–765.

    Google Scholar 

  16. Lips P, Bouillon R, van Schoor NM, Vanderschueren D, Verschueren S, Kuchuk N, Milisen K, Boonen S. Reducing fracture risk with calcium and Vitamin D. Clinical Endocrinology (2010) 73, 277–285.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Krankenhaus der Barmherzigen Schwestern, Wien, Austria

    Angela Trubrich, C. Bittighofer & H. Resch

  2. II. Medizinische Abteilung mit Rheumatologie/Osteologie & Gastroenterologie, KH der Barmherzigen Schwestern, Akademisches Lehrkrankenhaus der Medizinischen, Universität Wien, Stumpergasse 13, 1060, Wien, Austria

    Angela Trubrich

Authors
  1. Angela Trubrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Bittighofer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Resch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angela Trubrich.

Zusatzmaterial online

Das Zusatzmaterial kann unter folgendem Link abgerufen werden.

ESM 1 (PDF 1674 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trubrich, A., Bittighofer, C. & Resch, H. Fortschritte in der Osteoporosetherapie. rheuma plus 10, 6–9 (2011). https://doi.org/10.1007/s12688-011-0014-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12688-011-0014-0

Search

Navigation